| Document |
Document Title |
|
WO/2023/106376A1 |
The purpose of the present invention is to provide a novel material that promotes the production of collagen and/or hyaluronic acid and/or activates human epidermal keratinocytes. A lactic acid bacterium belonging to the genus Fructobaci...
|
|
WO/2023/102111A1 |
The present disclosure provides methods, uses, kits, and compositions comprising a compound of Formula (I), and either a second compound of Formula (I) or a compound of Formula (II). In one aspect, the methods are for treating a neurolog...
|
|
WO/2023/099902A1 |
An ion channel modulator for use in the treatment of cancer and/or metastasis is provided. The ion channel modulator is capable of facilitating ion flow through sodium leak channel (NALCN). A pharmaceutical composition comprising an ion ...
|
|
WO/2023/101441A1 |
The present invention relates to a use of microsomal triglyceride transfer protein (MTP) inhibitor in the treatment of fibrosis disease and, more specifically, to a novel use of an MTP inhibitor which exhibits an inhibitory effect on the...
|
|
WO/2023/100925A1 |
Provided is an asymmetric cell division inhibitor with which infertility due to aging or the like can be ameliorated. The asymmetric cell division inhibitor includes a spontaneous activation inhibitor that inhibits asymmetric cell divi...
|
|
WO/2023/100691A1 |
The present disclosure relates to providing a substance and a composition that promote the proliferation of epidermal stem cells and are effective in improving wrinkles and barrier function from the viewpoint of maintaining or improving ...
|
|
WO/2023/100829A1 |
The present invention provides a novel MuSK antibody. The present invention provides a molecule which binds to a target antigen, and is characterized by comprising a region that binds to the target antigen, a first peptide that recogni...
|
|
WO/2023/100380A1 |
[Problem] In the present invention, the action of DHMBA on metastatic human prostate cancer cells (PC-3 and DU-145) is examined. As a result, it is confirmed that DHMBA inhibits the growth of prostate cancer cells and enhances the death ...
|
|
WO/2023/100077A1 |
Compositions and methods directed to a synergistic blend of amino acids for providing a health benefit to an animal are disclosed herein. The blend can include a synergistic combination of glycine, methionine, cysteine, and glutamine
|
|
WO/2023/100740A1 |
This adhesive patch is characterized by comprising a support and a pressure-sensitive adhesive layer provided on the support, and is characterized in that the pressure-sensitive adhesive layer contains a local anesthetic, a thermoplastic...
|
|
WO/2023/100852A1 |
The purpose of the present invention is to provide a stabilized radiopharmaceutical composition wherein the decrease in the radiochemical purity over time is suppressed even in the case where the radioactivity concentration is high immed...
|
|
WO/2023/095929A1 |
Provided are: an agent for treatment of malignant tumors, the agent being characterized by containing an immune checkpoint inhibitor and by being used in combination with a boron neutron capture therapy; (i) an immune checkpoint inhibito...
|
|
WO/2022/174037A9 |
Provided herein are methods of treating Pompe disease comprising administering a population of recombinant human acid a-glucosidase molecules or a pharmaceutical composition or formulation thereof, and a pharmacological chaperone.
|
|
WO/2023/095510A1 |
The invention provides a means for a treatment for a demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, and also for reducing the risk of...
|
|
WO/2023/094580A1 |
The present invention relates to an oral anti-ageing composition comprising a mixture of: - At least one ingredient chosen from the group of niacinamide mononucleotide (NMN), niacinamide riboside (NR) and niacin - Resveratrol and/or pter...
|
|
WO/2023/095305A1 |
The invention provides a means for a treatment for a demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, and also for reducing the risk of...
|
|
WO/2023/096330A1 |
The present invention relates to a composition which is for promoting angiogenesis and comprises thymosin β-4 fusion proteins. The thymosin β-4 fusion proteins according to an aspect of the present invention can very effectively pass t...
|
|
WO/2023/096448A1 |
The present invention relates to a use of Obatoclax in treating metabolic and fibrotic diseases, and more specifically, to a novel use of Obatoclax in preventing or treating metabolic and fibrotic diseases, wherein Obatoclax exhibits the...
|
|
WO/2023/096446A1 |
The present invention relates to a use of etravirine in the treatment of metabolic diseases and fibrotic diseases, and more specifically, to a novel use of etravirine in the prevention or treatment of metabolic diseases and fibrotic dise...
|
|
WO/2023/097119A2 |
The present invention provides methods of treating a disease or disorder in a subject comprising administering to the subject a therapeutically effective amount of an agent that modulates RIOK2.
|
|
WO/2023/092465A1 |
The present invention relates to an application of Brazil hematoxylin in the preparation of an inhibitor of an anti-apoptotic protein Mcl-1. Specifically disclosed is use of Brazil hematoxylin as an inhibitor or a competitive binding age...
|
|
WO/2023/096313A1 |
The present disclosure relates to a flavanone derivative compound useful in the treatment or alleviation of fibrosis and medical use thereof.
|
|
WO/2023/095874A1 |
The present invention addresses the problem of providing a technology for improving the cell-binding properties of a liposome, an exosome or a lipid nanoparticle, and provides a lipid compound having a group represented by general formul...
|
|
WO/2023/095860A1 |
The present invention provides a medicine useful for treating and/or preventing COVID-19. Provided is a medicine characterized by combining: (A) a compound represented by formula (I) (where: Y is N; R1 represents an optionally substitute...
|
|
WO/2023/089052A1 |
The invention relates to pharmaceutical compositions and methods of treating autophagy related diseases and disorders, and in particular neurological and/or CNS-related diseases. The present invention relates to compounds according to Fo...
|
|
WO/2023/089313A1 |
There is described a compound for use in the treatment of a mitochondrial DNA disorder, wherein the compound is a glycolysis inhibitor, an inhibitor of glutamine consumption or is L-asparaginase or pegaspargase. The glycolysis inhibitor ...
|
|
WO/2023/090260A1 |
The purpose of the present invention is to provide a composition for inhibiting histamine-N-methyltransferase. The present invention relates to a composition for inhibiting histamine-N-methyltransferase, said composition including L-ergo...
|
|
WO/2023/088062A1 |
The present invention provides an anti-hypoxic/anoxic injury use of a magnolol and/or honokiol aromatic ring amino-substituted derivative, and a pharmaceutical composition. The magnolol and/or honokiol aromatic ring amino-substituted der...
|
|
WO/2023/091127A1 |
An active ingredient complex is effective to treat, reduce the likelihood of developing, reduce the severity of, or ameliorate acute alcoholic liver damage or the symptoms of a hangover. In some embodiments, the active ingredient complex...
|
|
WO/2023/089074A1 |
The invention relates to pharmaceutical compositions and methods of treating autophagy related diseases and disorders, in particular for a systemic treatment thereof. The present invention relates to compounds according to Formula (I) or...
|
|
WO/2023/090313A1 |
The purpose of the present invention is to newly discover a transient receptor potential ankyrin 1 (TRPA1) agonist that exhibits an action for increasing the amount of food ingested, to provide a novel agonist of TRPA1, or to provide a n...
|
|
WO/2023/090355A1 |
Provided are an angiogenesis material, a bone-regeneration-promoting material, a method for producing an angiogenesis material, and a method for producing a bone-regeneration-promoting material that particularly enhance angiogenesis abil...
|
|
WO/2023/090411A1 |
Provided is a pharmaceutical composition for treating and/or preventing at least one among heart disease, heart disease complications, skeletal muscle disease, and skeletal muscle disease conditions, the pharmaceutical composition having...
|
|
WO/2023/089131A1 |
The invention relates to an antibody or a fragment thereof that binds specifically to the S100A4 protein for use in the prevention and/or treatment of a disease associated to pathogenic fibrosis. The invention also relates to in vitro me...
|
|
WO/2023/090409A1 |
In one embodiment, the present invention pertains to a peptide having affinity for the human transferrin receptor, and to applications of the same, wherein in order to pass through the blood-brain barrier, the peptide can be used by bind...
|
|
WO/2023/090381A1 |
Disclosed is a new anti-HBV agent targeting host factor DOCK11. This anti-HBV agent contains, as an active ingredient, a substance which binds to DOCK11 and inhibits the function of DOCK11. In one embodiment, the anti-HBV according to th...
|
|
WO/2023/090366A1 |
The present invention addresses the problem of providing an anticancer agent and/or a cardiac-function-improving agent having a novel action mechanism. A pharmaceutical composition containing, as an active ingredient, a substance that in...
|
|
WO/2023/085396A1 |
The present invention relates to providing a pharmaceutical composition that is useful for treating Alport syndrome. The present invention provides a pharmaceutical composition that is useful for treating Alport syndrome and contains a c...
|
|
WO/2023/086796A2 |
Provided are methods for treating cancer by converting tumor-resident macrophages into a hybrid M1/M2 macrophage phenotype; this phenotype has attributes that are advantageous for cancer therapy. Hybrid markers include (lower than M2, hi...
|
|
WO/2023/086465A1 |
The present disclosure provides LNPs comprising payload molecules, e.g., mRNA therapeutics, for the treatment of diseases or disorders, which would benefit from delivery of payload molecules to airway cells.
|
|
WO/2023/085351A1 |
The present invention addresses the problem of providing a means capable of properly controlling differentiation of T-cells in order to avoid hyperactivation of T-cells after T-cell stimulation caused by superantigens, etc., and avoid re...
|
|
WO/2023/085787A1 |
The present disclosure provides a composition for removing senescent cells that is useful in senescent cell removal. The composition of the present invention induces the apoptosis of senescent cells and thus can be usefully applied to th...
|
|
WO/2023/085741A1 |
The present invention relates to a composition for preventing or treating multiple organ failure caused by infection, comprising 3'-sialyllactose, 6'-sialyllactose, or a salt thereof as an active ingredient. More particularly, as a resul...
|
|
WO/2023/085440A1 |
Provided is a therapeutic agent or the like that is for refractory viral infections and that is capable of eliminating or decreasing cccDNA in hepatocytes. This therapeutic agent for refractory viral infections according to the present i...
|
|
WO/2023/085300A1 |
The present invention provides a pharmaceutical composition in which valemetostat or a pharmaceutically acceptable salt thereof, particularly valemetostat tosylate, has an excellent elution property. It was found that an excellent elut...
|
|
WO/2023/084800A1 |
Provided is a new ophthalmic solution which can suppress the progression of a keratoconjunctival epithelial disorder during eye dropping, and can be used for the treatment of glaucoma for a long period of time. The solution contains tafl...
|
|
WO/2023/083293A1 |
Provided in the present invention is a variety of pharmaceutically acceptable salts of eliglustat, comprising a napadisylate, oxalate, glutarate, mucate and various crystal forms thereof. Further provided are a pharmaceutical composition...
|
|
WO/2023/083980A1 |
The present disclosure concerns the use of 3α-ethynyl-3β-hydroxy-5α-androstan-17-one as medicament, in particular in treatment of a disease or disorder associated with an α3 subtype of the GABAA receptor. The present disclosure is sp...
|
|
WO/2023/083343A1 |
Among other things, the present disclosure provides technologies, e.g., compounds, compositions, methods, use for preventing or treating various conditions, disorders or diseases. In some embodiments, a condition, disorder or disease is ...
|
|
WO/2023/085420A1 |
The present invention provides a means whereby it is possible to clarify the mechanism of manifestation of symptoms, an illness, or dysfunction caused by mitochondrial dysfunction and prevent or treat symptoms, an illness, or dysfunction...
|
